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The CD40/CD40 Ligand System
Linking Inflammation With Atherothrombosis
Charalambos Antoniades, MD, Constantinos Bakogiannis, MD, Dimitris Tousoulis, MD, PHD,
Alexios S. Antonopoulos, MD, Christodoulos Stefanadis, MD
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The role of CD40/CD40 ligand (CD40L) in atherothrombosis is now widely accepted. However, the exact mecha-
nisms linking the CD40/CD40L system and the soluble form of CD40 ligand (sCD40L) with atherothrombosis
are currently a topic of intensive research. CD40L and sCD40L belong to the tumor necrosis factor superfamily,
and they are molecules with a dual prothrombotic and proinflammatory role. They are expressed in a variety of
tissues such as the immune system (in both B and T cells), the vascular wall, and activated platelets. Soluble
CD40L has multiple autocrine, paracrine, and endocrine actions, and it may trigger key mechanisms participat-
ing in atherothrombosis. CD40/CD40L may participate in the development of coronary atherosclerosis and the
triggering of acute coronary syndromes, while sCD40L seems to have a prognostic role not only in subjects with
advanced atherosclerosis but also in the general population. Although conventional cardiovascular medication
such as antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors, and many others have been
shown to reduce both sCD40L and cardiovascular risk, it is still unclear whether specific treatments targeting
the CD40/CD40L system will prove to be beneficial against atherothrombosis in the near future. (J Am Coll
Cardiol 2009;54:669–77) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.076b
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guring the last decade, the links between the immune
ystem and atherothrombosis have been well documented,
n a way that atherosclerosis is now considered to be an
nflammatory disease (1). Therefore, as atherosclerosis has
ecome an epidemic in the Western world, the investigation
f the key inflammatory mechanisms involved in atherogen-
sis is crucial for the design of therapeutic strategies target-
ng cardiovascular disease.
Over the recent years, it has been well established that
nteractions between CD40 and its immunomodulating
igand (CD40L), expressed in a variety of cell types includ-
ng platelets, vascular wall cells, and immune cells, are
ctively involved in atherogenetic and thrombotic mecha-
isms and may serve as a link between inflammation,
therosclerosis, and thrombosis (2).
tructure of CD40/CD40L
nd Regulation of its Expression
D40 is a type I transmembrane protein receptor and a
ember of the tumor necrosis factor superfamily, and its
ene is located in chromosome 20 (q12-q13.2) (2). Despite
he initial suggestion that CD40 exists as a dimer that is
rom the 1st Department of Cardiology, University of Athens Medical School,
thens, Greece. Dr. Antoniades is supported by a reintegration grant within the 7th
uropean Community Framework Programme.r
Manuscript received December 30, 2008; revised manuscript received March 5,
009, accepted March 10, 2009.eing trimerized after CD40L binding, recent studies de-
cribed CD40 as a constitutional trimer complex on cell
urface (Fig. 1) (3).
The B cells are the main cell type expressing CD40;
owever, CD40 is also expressed on other immunity cells,
pithelial cells, fibroblasts, and vascular wall cells such as
ndothelial cells (ECs) and smooth muscle cells (SMCs), as
ell as in platelets (4). In addition, the majority of these
ells also coexpress the CD40L receptor. Expression of
D40 is induced by proinflammatory stimuli, such as
nterleukin (IL)-1, -3, and -4, tumor necrosis factor-alpha,
nd interferon-. CD40 is regularly up-regulated within 6
o 12 h after the initial stimulation, remaining on the cell
urface for 24 to 72 h (4). Transcriptional factors, such as
uclear factor-kappa B and activator of transcription ki-
ases, are known to regulate CD40 expression (4). Simi-
arly, proinflammatory cytokines and oxidized low-density
ipoprotein induce the expression of CD40L gene, which is
ocated at chromosome X (q26.3-q27.1) (5).
After its ligation, CD40 is activated and the receptor is
nternalized into the cell (2). The activated receptor then
inds to members of the tumor necrosis factor receptor–
ssociated factor family and stimulate downstream signaling
athways, including nuclear factor-kappa B, with subse-
uent up-regulation of proinflammatory and proatherogenic
enes (6).
Platelets express CD40L after stimulation with a wideange of platelet activators, such as thrombin and thrombin
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collagen, phorbol myristate ace-
tate, and so forth (7). The first
studies reported that CD40L ex-
pression on platelet surface is de-
pendent on intracellular calcium
(Ca2) concentrations and pro-
tein kinase C activation (7). El-
evated release of soluble CD40
ligand (sCD40L) has also been
observed in platelets from dia-
betic patients after stimulation
with thrombin or thrombin re-
ceptor activation peptide (8). It
was also found that insulin resis-
tance as well as glucose and ad-
vanced glycation end products
nduce sCD40L release from platelets and increase CD40L
xpression in murine megakaryocytes (8). Finally, platelet
D40/CD40L expression is also partly regulated by nitric
xide signaling (9). Indeed, as reported by Schafer et al. in
n elegant clinical study (9) and in an animal model (10),
nhibition of nitric oxide synthase in humans results in
educed phosphorylation of platelet vasodilator-stimulated
hosphoprotein, and induces platelet activation that over-
xpress CD40. A similar overexpression of CD40 was also
bserved in streptozotocin-induced diabetic mice, suggest-
ng that diabetes may result in platelet activation and CD40
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
AMI  acute myocardial
infarction
CAD  coronary artery
disease
CD40L  CD40 ligand
EC  endothelial cell
GP  glycoprotein
IL  interleukin
sCD40L  soluble CD40
ligand
SMC  smooth muscle cell
Figure 1 Structure of CD40 Receptor, CD40L, and sCD40L
The CD40 protein, which is a type I transmembrane receptor, exists in trimers,
and this trimerization is crucial for its activation. The extracellular region of
CD40 is cysteine-rich (consisting of 20 residues). The CD40 protein consists of
4 cysteine-rich domains, and every domain is divided into 2 cysteine modules
(A1, A2, B1, B2). The CD40 ligand (CD40L) protein is a type II membrane pro-
tein with an intracellular amino terminus and an external carboxy terminus. Its
extracellular region belongs to the tumor necrosis factor (TNF) superfamily. The
CD40L is stored in -granules in unstimulated platelets but rapidly translo-
cates to the platelet surface when platelets are activated. The surface-ex-
pressed CD40L is then cleaved and shed from the platelet surface as soluble
CD40 ligand (sCD40L). C  C-terminal; N  N-terminal.bverexpression partly by decreasing nitric oxide bioavailabil-
ty (10).
D40L in Stable and Acute Coronary Syndromes
ACS): Insights From Basic Science
therogenesis and plaque stability. CD40/CD40L ex-
ression is known to be up-regulated in atheroma-
ssociated cells but the exact regulating mechanisms remain
argely unknown (5,11). In vitro studies have shown that
D40/CD40L interactions on the EC surface result in
ndothelium and SMC activation and subsequent adhesion
olecules expression, an initiating step in atherogenesis
5,11). In addition, recent evidence suggests that CD40/
D40L has a role in dendritic cells and T-lymphocytes
nteractions inside the vascular wall (12). Indeed, mapping
f activated dendritic cells in human carotid and coronary
theroma demonstrated that CD40L affects dendritic cell
aturation; activated and fully mature dendritic cells regu-
ate T-cell infiltration, characteristic for unstable coronary
theroma (13). Furthermore, sCD40L has an unfavorable
ffect on the vascular redox state and endothelium-
ependent relaxation, through activation of specific redox-
ensitive intracellular pathways. Cell and animal studies
emonstrate that CD40L destabilizes endothelial nitric
xide synthase messenger ribonucleic acid and increases
ascular oxygen production (14). Therefore, proinflamma-
ory cytokines, reduced nitric oxide bioavailability, and
verexpression of adhesion molecules promote leukocyte
ecruitment and migration into tunica media, participat-
ng in atheroma formation (Fig. 2) (11). In addition,
nteractions between CD40L and CD40 also affect the
elease of adipokines from adipocytes, contributing to
therogenesis (15).
Further to the interaction between CD40L and CD40,
irlik et al. (16) demonstrated that sCD40L also interacts
ith the monocyte/macrophage integrin Mac-1, resulting in
ac-1–dependent adhesion and migration of inflammatory
ells. In addition, CD40L/ mice show significantly re-
uced invasion of inflammatory cells into the peritoneal
avity compared with CD40/ and wild-type controls,
uggesting the CD40L promotes atherogenesis partly inde-
endently of its classic receptor CD40 (Fig. 2) (16).
Evidence suggests that CD40/CD40L interactions in-
uce the expression of matrix metalloproteinases that de-
rade interstitial collagen and the thin fibrous cap of
theromatous plaques, leading to plaque instability and
upture (11). Indeed, inhibition of CD40L signaling en-
ances atheroma collagen content in mice (11), whereas it
as been suggested that CD40L triggers apoptosis and
nduces the formation of necrotic core in atherosclerotic
laque (11). Furthermore, recent evidence suggests that
D40/CD40L interactions promote in vivo angiogenesis by
p-regulating local vascular endothelial growth factor and
asic fibroblastic growth factor expression, affecting in
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August 18, 2009:669–77 CD40/CD40 Ligand and Atherothrombosishis way intraplaque neovascularization and plaque vul-
erability (17).
latelet activation and thrombus formation. Further to
theroma formation and plaque weakening, CD40/CD40L
nteractions have an eminent role in thrombotic events after
laque rupture. The CD40/CD40L interactions induce
issue factor expression on macrophages and ECs and
iminish thrombomodulin expression, favoring a local pro-
oagulant and prothrombotic status (18). In addition, the
nhibitory role of sCD40L on EC-derived nitric oxide
ioavailability may further promote local prothrombotic
tate (14). Finally, CD40/CD40L interaction inhibits EC
igration at the site of the plaque erosion, blocking the
e-endothelization process (11).
Platelets are the main source of sCD40L, being respon-
ible for 95% of circulating sCD40L levels (Fig. 1) (19).
D40L stabilizes arterial thrombi by a beta-3 integrin-
ependent mechanism that results in platelet activation by
utside-in signaling (Fig. 2) (20). Indeed, apart from its
eceptor, sCD40L also binds to the glycoprotein (GP)
Ib/IIIa platelet receptors, inducing their activation, and GP
Ib/IIIa antagonists reduce sCD40L release from activated
Figure 2 CD40/CD40L and Atherothrombosis
Activated platelets express CD40 ligand (CD40L), which is then cleaved and relea
through both its receptor CD40 and through monocyte/macrophage integrin Mac-1
on endothelial cell (EC) surfaces, which are then activated (by triggering the overe
protein [AP]-1, and others) to express adhesion molecules such as E-selectin, vas
(ICAM-1) on EC surfaces. These molecules mediate the adhesion and transmigrati
(SMCs) also produce proinflammatory molecules such as monocyte chemoattracta
tissue factor; and they overexpress enzymes generating reactive oxygen species (R
(Ox-LDL) which is up-taken by activated macrophages, which are turned into foam
to further induce atherogenesis. Red rectangles  E-selectin; red receptors  Mac-1
NO  nitric oxide; VSMC  vascular smooth muscle cells.latelets in vitro (21). As we have recently shown, GPIa alatelet receptor may also regulate sCD40L release from
ctivated platelets (22). Carriers of the 807T polymorphism
n the GPIa gene, which regulates surface density of the
eceptor, express higher sCD40L levels during the acute
hase of myocardial infarction (22). Noticeably, healthy
arriers of the 807T allele also express higher levels of
CD40L in the presence of endothelial injury (22). How-
ver, there is evidence that sCD40L may not directly
romote atherogenesis (23), because previous studies in
ice suggested that CD40L modulates atherogenesis pri-
arily by its expression on nonhematopoietic cell types
ather than monocytes, T lymphocytes, or platelets (23).
herefore, as circulating sCD40L is mainly derived from
ctivated platelets, its association with atherothrombosis
ould be primarily due to its ability to reflect platelet
ctivation and less because of a direct impact in
therothrombosis.
Finally, CD40L (and possibly sCD40L) play a key role in
therothrombosis by being a link between platelets, inflam-
ation, thrombosis, and atherogenesis (18). The most
mportant mechanisms by which the CD40/CD40L axis
soluble CD40 ligand (sCD40L). The sCD40L binds to circulating monocytes
oting their adhesion to vascular endothelium. The sCD40L also binds to CD40
ion of transcriptional factors such as nuclear factor-kappa B [NF-], activator
ell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1
onocytes to subendothelial space. Activated ECs and smooth muscle cells
tein (MCP)-1 and interleukins (ILs); they release prothrombotic mediators such as
he ROS oxidize low-density lipoprotein (LDL) to oxidized low-density lipoprotein
D40L also activates SMCs and fibroblasts, which are proliferated and migrate
w triangles  VCAM; and blue triangles  ICAM. MMP  matrix metalloproteinase;sed as
, prom
xpress
cular c
on of m
nt pro
OS). T
cells. C
; yelloffects atherothrombosis are summarized in Figure 2.
C672 Antoniades et al. JACC Vol. 54, No. 8, 2009
CD40/CD40 Ligand and Atherothrombosis August 18, 2009:669–77D40L in Stable and Unstable Coronary SyndromesTable 1 CD40L in Stable and Unstable Coronary Syndromes
Study, First Author (Ref. #) Population Measures Outcome/Conclusion
Aukrust et al. (26) 26 patients with UA, 29 with stable
angina, and 19 controls
Serum levels of sCD40L and T-cell expression
of CD40L in UA; sCD40L after platelet and
T-cell stimulation; sCD40L induction of
MCP-1 synthesis from PBMCs
Higher sCD40L levels and CD40L expression
on T cells in patients with UA; sCD40L
enhances MCP-1 release in PBMCs;
enhanced sCD40L release after platelet
activation
Wang et al. (27) 20 patients with UA, 10 patients
with stable angina, and
10 controls who underwent
coronary angiography
Transcoronary concentration gradient of
sCD40L and hsCRP in patients with UA
(blood samples from coronary sinus,
aortic root, and femoral vein)
Higher sCD40L levels in UA and stable
angina; higher transcoronary gradient of
sCD40L in UA; higher sCD40L in patients
with complex lesions
Yan et al. (25) 20 patients with UA, 24 with
stable angina, 12 with AMI, and
16 controls
Serum levels of sCD40L and CD40L
expression in PBMCs before and
after PTCA
Elevated levels of sCD40L in stable angina
and ACS; higher CD40L expression in
PBMCs in UA/AMI patients; marked
increase in sCD40L after PTCA
Peng et al. (28) 15 patients with AMI, 12 with UA,
23 with stable angina, and
30 controls
Comparison of serum levels of sCD40L in
ACS patients; correlation between sCD40L
levels and adhesion molecules
Higher levels of sCD40L, sICAM-1, and
sVCAM-1 in ACS; sCD40L positively
correlated with sICAM-1, sVCAM-1,
triglycerides, and apolipoprotein B, and
negatively correlated with HDL-C
Garlichs et al. (29) 15 patients with AMI, 25 with UA,
15 with stable angina, and
12 controls who underwent
coronary angiography or PCI
Serum levels of sCD40L and platelet CD40L at
baseline and after 6 months of follow-up
Higher sCD40L levels and CD40L platelet
expression in UA/AMI; lower CD40L
expression after 6 months of follow-up
Tousoulis et al. (31) 109 patients with AMI, 201
patients with stable CAD, and
286 controls
Circulating levels of sCD40L, VCAM-1,
sICAM-1, and IL-6
Higher sCD40L and IL-6 levels in AMI; higher
sICAM-1 and VCAM-1 levels in AMI and
stable angina group; IL-6 was
independently associated with sCD40L
only in controls
Ko et al. (35) 18 patients with AMI scheduled
for PCI
Levels of sCD40L in culprit coronary artery
and relation to circulating levels
sCD40L levels were significantly higher in
culprit coronary artery compared with
femoral vein
Malarstig et al. (30) 24-month follow-up of 2,359
patients with NSTEMI from the
FRISC II trial, randomized to
receive early invasive or
conservative treatment with
dalteparin or placebo
Prognostic value of sCD40L levels in ACS,
effect of 3459AG single nucleotide
polymorphism, and treatment with
dalteparin on sCD40L levels
In placebo group, sCD40L levels above
median (290 pg/ml) were associated
with increased AMI risk; dalteparin
reduced AMI risk in patients with sCD40L
levels above median 3459AG
polymorphism associated with increased
sCD40L levels
Ohashi et al. (34) 17 patients with AMI and
10 patients with UA who
underwent PCI
Coronary sinus and arterial levels of sCD40L,
association with end-diastolic index or
ejection fraction; CD40L expression in
intracoronary thrombi
Transcardiac gradient of sCD40L increased
at 9 h in both groups; high CD40L
expression in thrombi; association
between sCD40L and MMP-9 activity in
AMI; aspirating thrombectomy reduced
sCD40L levels
Tayebjee et al. (32) 204 patients who attended for
cardiac catheterization for
investigation of suspected
stable CAD
Plasma levels of sCD40L in patients with
CAD, possible relation to angiographically-
proven severity of the CAD
Higher sCD40L in CAD; no relation with
severity of the CAD
Rondina et al. (36) 909 patients undergoing
angiography; 303 patients with
CAD with a cardiac event within
1 year, 303 with CAD without
event, 303 without CAD or event
Prognostic value of sCD40L Higher sCD40L levels associated with
decreased risk of CAD in non-ACS
patients
Martins et al. (37) 865 patients with chest pain,
with or without angiographically
confirmed CAD, with or
without AMI
Plasma concentrations of CD40L There was no difference in sCD40L levels
between CAD and non-CAD patients
Antoniades et al. (22) 219 patients with premature AMI
and 389 controls; followed up
for 1 year
Circulating sCD40L and vWF levels measured
at baseline (during acute phase of AMI)
and after 1 year; impact of genetic
polymorphisms C807T and A1648G on
platelets glycoprotein Ia on sCD40L levels
was evaluated
Patients with AMI had higher sCD40L levels
compared with controls; sCD40L levels
were significantly reduced after 1 year in
the same subjects; C807T was an
independent predictor of sCD40L levels
during AMI and after 1 year; C807T was
associated with sCD40L levels in healthy
controls only with high vWF levelsContinued on next page
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August 18, 2009:669–77 CD40/CD40 Ligand and AtherothrombosisD40L in Stable and ACS:
nsights From Clinical Studies
fter the initial observations from basic science supporting
hat CD40L perpetuates inflammation and induces throm-
us formation in experimental models (1), many studies
ave examined the potential role of CD40/CD40L inter-
ctions in ACS and stable coronary artery disease (CAD) at
clinical level. These studies have demonstrated that
irculating sCD40L levels are significantly higher in pa-
ients with acute myocardial infarction (AMI) or unstable
ngina, compared with healthy persons (22,24 –33)
Table 1). Indeed, it appears that a gradual increase in
CD40L levels takes place with ACS progression (26,28).
ranscoronary sCD40L levels exhibit an early peak just 9 h
fter onset of AMI or unstable angina (27,34). However,
here is no significant difference between AMI and unstable
ngina patients in circulating sCD40L levels (24). Interest-
ngly, intracoronary CD40L levels are higher in the culprit
oronary artery than in the peripheral circulation, reflecting
he activation of a potent local inflammatory process
27,31,35).
As we have recently shown, sCD40L levels are indepen-
ent from the underlying proinflammatory state in AMI or
AD patients, as assessed by circulating levels of IL-6,
oluble intercellular adhesion molecule-1, and soluble vas-
ular cell adhesion molecule-1 (24). Conversely, in healthy
ubjects, sCD40L is strongly associated with IL-6 serum
evels (24). Therefore, it seems that in patients with AMI or
AD, circulating sCD40L may be dominantly dependent
n sCD40L release from activated platelets and to a lesser
xtent on inflammatory status, which is a major determinant
f sCD40L in healthy subjects (24). Although the clinical
mportance of circulating sCD40L in ACS is still contro-
ersial (28), it seems that measurement of sCD40L can be
valuated either as an inflammatory marker or as a marker of
latelet activation, depending on the underlying disease
tate.
The vast majority of data regarding stable CAD are
erived from clinical studies comparing the effect of CD40/
D40L interactions in ACS with the effect in stable CAD
nd healthy subjects. As we (24) have shown, plasma
CD40L is higher in patients with stable angina than in
ontinuedTable 1 Continued
Study, First Author (Ref. #) Population
Plaikner et al. (33) 1,089 consecutive patients in an
emergency department for
medical or neurologic
emergencies
Diagno
AMI
CS acute coronary syndrome; AMI acutemyocardial infarction; CAD coronary artery disease; CD
I; HDL-Chigh density lipoprotein cholesterol; hsCRPhigh sensitivity C-reactive protein; IL interleuk
levationmyocardial infarction; PBMCperipheralbloodmonocytecell;PCIpercutaneouscoronary inte
ntercellular adhesion molecule; sVCAM soluble vascular cell adhesion molecule; TF  tissue factoealthy subjects, but lower compared with patients with tCS (24). Indeed, multiplicity of risk factors is associated
ith a summing effect, leading to an even higher increase in
CD40L levels in CAD patients (24), although there is a
ide variation between different clinical studies (Table 1)
29,36,37).
Circulating sCD40L levels in stable or unstable coronary
yndromes are also affected by genetic determinants. Ge-
etic polymorphism A3459G on sCD40L has been re-
orted as a determinant of sCD40L levels, with carriers of
459G allele having elevated sCD40L levels during ACS
30). We have previously demonstrated that genetic poly-
orphisms affecting the expression of GPIa on platelets’
urface (such as C807T polymorphism on the GPIa gene)
ay affect sCD40L levels in clinical conditions such as
table CAD or AMI, whereas this effect is not observed in
ealthy persons, in whom platelet activation is not the
riving force of circulating sCD40L (22).
Taken together, these complex mechanisms regulating cir-
ulating sCD40L levels in humans make the interpretation of
his biomarker extremely difficult, limiting its clinical use.
ethodological Considerations
egarding Measurement of sCD40L in Humans
number of methodological issues regarding the measure-
ent of circulating sCD40L levels in humans may partly
xplain the controversial results provided by the various
linical studies. In more detail, a recent study reported that
ample preparation may substantially influence sCD40L
evels, suggesting that increased sCD40L levels may result
rom in vitro platelet activation (38). Therefore, it has been
uggested that plasma samples are more suitable for
CD40L measurements because serum sCD40L levels are
orrelated with platelet count and reflect their in vitro
ctivation status (36). Furthermore, whole blood should be
ssessed as soon as possible after blood sampling. Prolonged
eeping (3 h) at room temperature before freezing may lead
o a false increase in sCD40L levels, whereas temporary
torage at 4oC has minimal effects on plasma sCD40L (39).
mportantly, sCD40L levels appear to have diurnal varia-
ions (being elevated during the light phase compared with
he dark phase) (40), indicating the need for standardizing
Measures Outcome/Conclusion
lue of plasma sCD40L levels for
emic stroke
In adults presenting to emergency
department, sCD40L is not useful as a
diagnostic marker for acute cardiac,
cerebrovascular ischemic, or
thromboembolic events
D40 ligand; FRISC II Fragmin and fast Revascularization during InStability in Coronary artery disease
monocyte chemoattractant peptide;MMPmatrixmetalloproteinase; NSTEMInon–ST-segment
;PTCApercutaneous transluminal coronaryangioplasty; sCD40LsolubleCD40 ligand; sICAMsoluble
unstable angina; VCAM  vascular cell adhesion molecule; vWF  von Willebrand factor.stic va
or isch
40LC
in;MCP
rvention
r; UA ime of blood sampling in clinical studies.
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CD40/CD40 Ligand and Atherothrombosis August 18, 2009:669–77D40L and CAD Prognosis
growing body of evidence has shed light on many aspects
f the role of CD40L in cardiovascular disease, and it has
een supported that it may have a predictive value (41–46)
Table 2). In the Women’s Health Study, high sCD40L
D40L and Risk Prediction in Coronary Artery SyndromesTable 2 CD40L and Risk Prediction in Coronary Artery Syndrom
Study, First Author (Ref. #) Population
Schonbeck et al. (47) 130 women who had AMI, stroke, or
death during 4 years follow-up and
130 controls, from WHS
Heeschen et al. (19) 1,088 patients with ACS, 626 with
acute chest pain (controls) from the
CAPTURE trial
Kinlay et al. (48) 2,908 subjects from the MIRACL study
Dominguez-Rodriguez et al. (41) 96 patients with STEMI
Liang et al. (50) 66 patients with CAD progression in
follow-up and 124 patients with no
CAD progression on repeated
angiography
Manenti et al. (42) 172 patients with non–ST-segment
elevation ACS
Olenchock et al. (52) 2,403 ACS patients from placebo arm
of the OPUS-TIMI 16 trial
Tanne et al. (51) 203 patients with CAD who had AMI,
sudden cardiac death, or ischemic
stroke and 203 control subjects
Cipollone et al. (43) 70 patients who underwent PTCA
Turker et al. (44) 36 patients with stable angina who
underwent PCI and stent
implantation
Apple et al. (45) 455 patients presenting on admission
with ACS
Morrow et al. (53) 1,524 patients presenting within 24 h
of onset of non–ST-segment elevation
ACS in the TACTICS-TIMI 18 trial
L’Allier et al. (49) 53 patients who underwent balloon
angioplasty
Ferro et al. (46) 231 patients with permanent or
persistent atrial fibrillation, and
54 with paroxysmal atrial fibrillation
APTURE C7E3 Fab Anti-Platelet Therapy in Unstable Refractory angina; GP glycoprotein; MIRA
ith Unstable coronary Syndromes; STEMI  ST-segment elevation myocardial infarction; TACTICS
IMI  Thrombolysis In Myocardial Infarction; WHS  Women’s Health Study; other abbreviationslasma levels were associated with a higher risk of major wardiovascular events (47). In the CAPTURE (c7E3 Fab
nti-Platelet Therapy in Unstable Refractory Angina) trial
19), patients with high sCD40L levels had an almost
-fold higher risk for cardiovascular death or AMI (19),
hereas in the MIRACL (Myocardial Ischemia Reduction
Measures Outcome/Conclusion
ognostic risk value of plasma sCD40L
levels in patients with AMI
High sCD40L (95th percentile)
levels associated with increased
risk for future cardiac events
ognostic risk value of sCD40L levels;
possible improvement of cardiac risk
after the use of abciximab
Higher sCD40L associated with
increased risk of death or AMI in
ACS group and controls. Abciximab
reduced cardiac risk in patients
with higher sCD40L levels
asma sCD40L levels High sCD40L associated with
increased cardiac risk. Atorvastatin
reduced cardiac risk but did not
affect sCD40L levels
D40L/IL-10 ratio as a better
prognostic marker in patients with
STEMI
sCD40L/IL-10 ratio was a better
predictor of in-hospital adverse
events in patients with STEMI
edictive role of sCD40L levels in CAD
progression
sCD40L did not have a predictive role
in CAD progression
provement of TIMI risk score
prognostic value with the use of
CD40L
CD40L could not add prognostic value
to the TIMI risk score for patients
with non ST-elevation ACS
sociation between sCD40L levels and
cardiovascular outcomes in patients
with ACS
There was no association between
sCD40L levels and cardiac events
such as death or AMI
sociation between sCD40L and risk
of coronary events in patients with
CAD
Increased sCD40L levels were not
associated with increased risk of
future coronary events in patients
with CAD
ssible relation of pre-procedural
sCD40L levels and restenosis risk
during 6 months of follow-up
Increased sCD40L levels were
associated with restenosis in
patients who underwent PTCA after
6 months follow up
sessing the association between
sCD40L levels and in-stent restenosis
risk during 6 months of follow-up
Increased pre-procedural sCD40L
levels is independent predictor of
in-stent restenosis in patients with
stable angina
ognostic value of sCD40L levels for
adverse cardiac events
No association between sCD40L
levels and risk of cardiac events in
patients with ACS was observed
ividual and combined with traditional
cardiac biomarkers (B-type
natriuretic peptide, hsCRP, cardiac
troponin-I) prognostic value of
sCD40L for ischemic events
No association between sCD40L
plasma levels and the risk for
recurrent ischemic events in
patients with non–ST-segment
elevation ACS treated with GP IIb/
IIIa receptor antagonist
D40L levels before intervention and
at 1- and 6-month follow-up and
relation to angiographic restenosis
Sustained elevation of serum CD40
ligand levels 1 month after
coronary angioplasty predicts
angiographic restenosis
asma levels of sCD40L and relation to
vascular events (stroke or AMI)
during follow-up (mean 27.8  8.8
months)
Enhanced soluble CD40L level is a
predictor of vascular events in
patients with nonvalvular atrial
fibrillation
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August 18, 2009:669–77 CD40/CD40 Ligand and AtherothrombosisCD40L was an independent risk factor for recurrent
ardiovascular events (19,48). Indeed, it has been suggested
hat combined assessment of CD40L and troponin-T levels
as better predictive value regarding AMI risk (30). More-
ver, carriers of the 3459AG polymorphism in the
D40L gene are at higher AMI risk, indicative of a causal
ole of sCD40L in the pathophysiology of ACS (30).
otably, a small prospective study suggested that high
CD40L levels predict angiographic restenosis in patients
ho undergo coronary angioplasty (49). In contrast, other
linical studies suggested that CD40L has no predictive
alue in patients with CAD (50,51) or ACS (52,53)
Table 2).
In conclusion, given the lack of a standardized method-
logical approach and the complexity of CD40L patho-
hysiology, clinical studies have yielded contradictory results
Table 2). Therefore, additional large prospective trials are
eeded to clarify the possible predictive value of sCD40L in
ardiovascular disease.
D40/CD40L as a
herapeutic Target in Atherosclerosis
ntiplatelet/antithrombotic agents. As activated platelets
re the main source of circulating sCD40L, antiplatelet
gents were among the first drugs studied for their CD40L-
owering properties. Clopidogrel, which acts via adenosine
iphosphate receptor inhibition, completely inhibits
CD40L release from adenosine diphosphate-stimulated
latelets; patients under clopidogrel treatment exhibit re-
uced CD40L platelet expression and circulating sCD40L
evels (54). Moreover, it was also found that both short- and
ong-term treatment with clopidogrel significantly reduces
CD40L levels in patients with stable CAD (55), although
recent study demonstrated enhanced expression of
D40L on platelets surface after 1 year of treatment with
lopidogrel 75 mg/day plus aspirin 325 mg/day in patients
ith CAD (56).
Cyclooxygenase-2 inhibition may also be a potential
arget. Patients receiving aspirin exhibit decreased sCD40L
elease from platelets after platelet activation with collagen
21). The GP IIb/IIIa receptor inhibitors, such as eptifi-
atide, abciximab, and tirofiban, inhibit platelet aggregation
s well as sCD40L release in vitro (21). The beneficial effect
f GP IIb/IIIa inhibitors has been also demonstrated in
linical studies. The GP IIb/IIIa antagonists appear to be
articularly beneficial for the subgroup of high-risk ACS
atients with increased sCD40L levels; abciximab signifi-
antly reduced cardiovascular risk in patients with elevated
CD40L levels in the CAPTURE trial (19). In addition, as
ncreased sCD40L levels reflect a prothrombotic state, the
RISC II (Fragmin and fast Revascularization during
nStability in Coronary artery disease II) study demon-
trated that low-molecular-weight heparin (dalteparin) re-
uces the risk of AMI in non–ST-segment elevation ACS
atients with high sCD40L levels (30,57). Ctatins. Multiple pleiotropic effects have been attributed to
tatins; recent in vitro studies have demonstrated that statins
an also reduce oxidized low-density lipoprotein–induced or
ytokine-induced CD40L expression on human umbilical
ein ECs, SMCs, and mononuclear phagocytes in a
oncentration-dependent way (5). Additionally, incubation
f activated platelets with atorvastatin leads to decreased
latelet-induced cycloxygenase-2 expression in human um-
ilical vein ECs (58). Therefore, statins may be actively
mplicated in platelet-endothelium interaction. Indeed, at a
linical level, statin treatment reduces plasma sCD40L
evels in patients with CAD (59). Notably, the MIRACL
tudy (48) demonstrated that early atorvastatin treatment
nitiation after ACS reduces the risk for future cardiovas-
ular events associated with high sCD40L levels; neverthe-
ess, atorvastatin treatment only slightly affected sCD40L
evels.
hiazolidinediones. Thiazolidinediones are peroxisome
roliferator-activated receptor- agonists, widely used in
ype 2 diabetes mellitus treatment. Evidence from in vitro
tudies suggests that different cell types, such as platelets or
Cs, treated with thiazolidinediones exhibit reduced ex-
ression of CD40L messenger ribonucleic acid or protein
evels (60). Rosiglitazone treatment for 12 weeks signifi-
antly reduced serum sCD40L levels in patients with type 2
iabetes mellitus and CAD compared with placebo (61),
lthough short-term rosiglitazone treatment failed to affect
CD40L levels in healthy persons (62), highlighting the
omplex mechanisms regulating sCD40L release in differ-
nt disease states.
ther strategies. Several studies have also investigated the
CD40L-lowering properties of various nutritional and
harmaceutical agents. Patients with AMI receiving n-3
atty acids on a daily basis for 12 months had significantly
educed sCD40L levels (63). Additionally, in vitro data
upport a potent effect of antioxidants on CD40L expres-
ion, even though it is still unknown if this efficacy confers
ny clinical benefits. Specifically, CD40L expression is
nhibited in activated platelets treated with antioxidants
uch as vitamin C, superoxide dismutase, or phospholipase
2 inhibitors (57). Other strategies such as angiotensin-
onverting enzyme inhibitors also reduce sCD40L levels in
arious subpopulations, as we have previously described
64). Finally, despite the stimulatory effect of homocysteine
n sCD40L release, the effect of homocysteine-lowering
reatment with folic acid on circulating sCD40L in CAD
atients remains controversial (65).
Despite these important findings, the role of CD40/
D40L as a direct therapeutic target in atherothrombosis
as been questioned, as both CD40L/ mice (66) and
umans receiving antibodies against CD40L (67) appear
o have higher rates of thromboembolic complications,
uggesting that inhibition of platelet CD40L may render
latelet plugs unstable. Indeed, Langer et al. (66) have
uggested that the interactions between CD40 and
D40L-immune complexes may derange platelet func-
t
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ations noted.
onclusions
D40L and its soluble counterpart, sCD40L, are molecules
ith prothrombotic and proinflammatory properties, ex-
ressed in a variety of tissues such as immunity cells,
ascular wall, and most importantly, platelets. Multiple
utocrine, paracrine, and endocrine effects have been attrib-
ted to CD40/CD40L, triggering all together atherothrom-
osis. Patients with both stable and unstable coronary artery
isease exhibit higher circulating sCD40L levels, and it is
ikely that sCD40L may have a predictive value. However,
number of questions need to be resolved in this area of
esearch in the coming years. The protocols measuring
erum or plasma sCD40L need to be standardized in clinical
ractice, as technical issues may explain the huge variation
f the findings across the literature. Importantly, evidence
uggests that reducing high sCD40L levels by the use of
onventional drugs such as antiplatelet agents and statins
ay lead to improved clinical outcome. However, it is still
nclear whether sCD40L can be used as a therapeutic target
n cardiovascular disease, as circulating sCD40L levels
eflect mainly platelet activation, and the direct involvement
f sCD40L (as opposed to membrane-bound CD40L) in
therogenesis has been questioned. Therefore, more clinical
tudies in different cohorts, using standardized methods for
easuring sCD40L, are required to elucidate these issues.
Although the development of therapeutic strategies spe-
ifically targeting CD40/CD40L seems promising, the use
f antibodies against CD40L has been associated with
hromboembolic events, and these data have weakened the
nthusiasm for future studies using CD40L/CD40 as a
irect therapeutic target in atherosclerosis. Upcoming re-
ults of long-awaited large clinical trials would hopefully
lucidate the potential use of CD40L (and/or sCD40L) as
reliable biomarker and therapeutic target in cardiovascular
isease.
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